Portage Biotech (PRTG) News Today $7.85 -0.18 (-2.24%) Closing price 03:59 PM EasternExtended Trading$7.88 +0.03 (+0.32%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRTG Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Portage Biotech (NASDAQ:PRTG) Stock Price Down 1.4% - Time to Sell?August 16, 2025 | americanbankingnews.comPortage Biotech Reports Results for Fiscal Year Ended March 31, 2025July 25, 2025 | globenewswire.comPortage Biotech Regains Nasdaq Compliance, Maintains Listing On Capital Market | NasdaqJune 27, 2025 | nasdaq.comPRTG Portage Biotech Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comPortage Biotech Inc. (PRTG) Income Statement - Yahoo FinanceJune 26, 2025 | finance.yahoo.comPortage Biotech Regains Nasdaq ComplianceJune 25, 2025 | tipranks.comPortage Biotech Regains Full Compliance with Nasdaq Continued Listing RequirementsJune 25, 2025 | globenewswire.comPortage Biotech Inc. (PRTG) Cash Flow - Yahoo FinanceJune 24, 2025 | finance.yahoo.comPortage Biotech acquires stake in Compedica for $5 millionJune 10, 2025 | investing.comPortage Biotech and Compedica Forge Strategic Alliance with Stock ExchangeJune 9, 2025 | tipranks.comPortage Biotech and Compedica Stock-for-Stock ExchangeJune 9, 2025 | globenewswire.comPortage Biotech Shares Rise on Confirmatory Trial Results, Plans for Human TrialApril 28, 2025 | marketwatch.comPortage Biotech stock soars on promising preclinical resultsApril 28, 2025 | za.investing.comPortage Biotech Stock Surges On New Preclinical Data In Mesothelioma Trial: Retail Gets More BullishApril 28, 2025 | msn.comPortage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7April 28, 2025 | globenewswire.comInsider Stock Buying Reaches US$2.15m On Portage BiotechApril 26, 2025 | finance.yahoo.comPortage Biotech Inc. Common Stock (PRTG) Pre-MarketMarch 30, 2025 | nasdaq.comPortage Biotech presents preclinical data for PORT-7March 28, 2025 | markets.businessinsider.comPortage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment TrialMarch 27, 2025 | marketwatch.comPortage Biotech stock soars on promising preclinical dataMarch 27, 2025 | investing.comPortage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7March 27, 2025 | markets.businessinsider.comPortage Biotech Resumes Patient Enrollment In Final Cohort Of Dose Escalation Stage For PORT-6March 14, 2025 | nasdaq.comPortage Biotech Inc. Announces New Director Compensation Plan and Stock Option GrantsMarch 13, 2025 | tipranks.comPortage resumes enrollment in final cohort of dose escalation for ADPORT-601March 12, 2025 | markets.businessinsider.comPortage Biotech Resumes Key Trial Enrollment, Advances Innovative Immunotherapy ApproachMarch 12, 2025 | tipranks.comPortage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 TrialMarch 12, 2025 | globenewswire.comPortage Biotech Inc.: Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing RequirementsFebruary 19, 2025 | finanznachrichten.dePortage Biotech Granted Nasdaq Compliance ExtensionFebruary 12, 2025 | tipranks.comPortage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing RequirementsFebruary 12, 2025 | globenewswire.comPortage Biotech Announces Completion of $2.15 Million Private FinancingJanuary 30, 2025 | globenewswire.comPortage announces relaunch of adenosine subsidiary as independently managedJanuary 7, 2025 | markets.businessinsider.comPortage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New CompanyJanuary 6, 2025 | globenewswire.comPortage Biotech trading resumesDecember 25, 2024 | markets.businessinsider.comPortage Biotech trading halted, volatility trading pauseDecember 25, 2024 | markets.businessinsider.comPortage Biotech Shares Double on Letter of Intent to Sell SubsidiaryDecember 17, 2024 | marketwatch.comPortage Biotech Stock More Than Doubles On Immunova Deal Potential: Retail Sees Big OpportunityDecember 17, 2024 | msn.comPortage Biotech Inc.: Portage Biotech Announces Receipt of Nasdaq Noncompliance LetterDecember 14, 2024 | finanznachrichten.dePortage Biotech receives noncompliance notification from NasdaqDecember 14, 2024 | markets.businessinsider.comPortage Biotech Inc. Appoints New CEO Amid Leadership ChangeDecember 13, 2024 | tipranks.comPortage Biotech Announces Receipt of Nasdaq Noncompliance LetterDecember 12, 2024 | globenewswire.comPortage Biotech Announces Key Leadership ChangesDecember 7, 2024 | markets.businessinsider.comPortage Biotech Reports Reduced Losses and Strategic PlansNovember 26, 2024 | tipranks.comPortage Biotech Inc. Reports Asset and Liability ChangesNovember 26, 2024 | tipranks.comPortage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024November 26, 2024 | globenewswire.comPortage Biotech's Market Cap Drops To US$4.3m Leaving Insiders With LossesNovember 17, 2024 | finance.yahoo.comUnited States shares lower at close of trade; Dow Jones Industrial Average down 0.25%September 19, 2024 | msn.comU.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.59%August 30, 2024 | msn.comShort Interest in Portage Biotech Inc. (NASDAQ:PRTG) Decreases By 88.1%August 27, 2024 | marketbeat.comPortage Biotech (NASDAQ:PRTG) Stock, Short Interest ReportAugust 25, 2024 | benzinga.comPortage Biotech Inc.August 25, 2024 | wsj.com Get Portage Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRTG Media Mentions By Week PRTG Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRTG News Sentiment▼0.000.70▲Average Medical News Sentiment PRTG News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRTG Articles This Week▼01▲PRTG Articles Average Week Get the Latest News and Ratings for PRTG and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Portage Biotech and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Akari Therapeutics News Clearside Biomedical News Mural Oncology News Synergy CHC News BioXcel Therapeutics News Dyadic International News Kezar Life Sciences News MIRA Pharmaceuticals News Tenax Therapeutics News Cadrenal Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRTG) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Portage Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Portage Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access